HPV Status as Prognostic Biomarker in Head and Neck Cancer—Which Method Fits the Best for Outcome Prediction?

By J. Kühn, W. Schmid, S. Körner, F. Bochen, S. Wemmert, Hugo Rimbach, S. Smola, J. Radosa, M. Wagner, L. Morris and 4 more. 2021

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “Regarding the significantly worse prognosis and different tumor cell biology of discordant (p16 − /HPV+ or p16+/HPV − ) HNSCC patients, the proof of a positive p16-and positive HPV-DNA PCR testing was mandatory for assigning positive HPV tumor status [17,18].”
Prognostic impact of intra- and peritumoral immune cell subpopulations in head and neck squamous cell carcinomas – comprehensive analysis of the TCGA-HNSC cohort and immunohistochemical validation on 101 patients (2023, background): “Regarding the significantly worse prognosis and different tumor cell biology of discordant (p16-/HPV+ or p16+/HPV-) HNSCC patients, the proof of a positive p16- and positive HPVDNA PCR testing was mandatory for assigning positive HPV tumor status (23, 24).”